Curis (CRIS) 10-Q 7 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 01, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'CRIS	'
Entity Registrant Name	'CURIS INC	'
Entity Central Index Key	'0001108205	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	86,004,857

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$10,156,360	$9,591,487
Investments	45,614,450	48,588,135
Short-term investment - restricted	13,877	13,877
Accounts receivable	4,843,412	1,477,188
Prepaid expenses and other current assets	363,375	495,260
Total current assets	60,991,474	60,165,947
Property and equipment, net	439,357	445,655
Long-term investments	3,257,209	10,726,685
Long-term investment - restricted	152,610	166,487
Goodwill	8,982,000	8,982,000
Other assets	78,312	104,034
Total assets	73,900,962	80,590,808
Current Liabilities:	'	'
Accounts payable	2,849,252	2,036,864
Accrued liabilities	1,509,632	1,911,479
Warrants	67,910	'
Current portion of long-term debt, net	5,498,670	2,610,174
Total current liabilities	9,925,464	6,558,517
Long-term debt, net	24,372,065	27,945,186
Warrants	'	716,786
Other long-term liabilities	191,076	196,734
Total liabilities	34,488,605	35,417,223
Commitments (Note 9)	'	'
Stockholders' Equity:	'	'
Common stock, $0.01 par value - 225,000,000 shares authorized; 87,227,703 shares issued and 86,004,857 shares outstanding at June 30, 2014; and 87,081,862 shares issued and 85,859,016 shares outstanding at December 31, 2013	872,277	870,819
Additional paid-in capital	808,342,990	806,660,340
Treasury stock (at cost, 1,222,846 shares)	-1,524,029	-1,524,029
Accumulated deficit	-768,286,282	-760,826,561
Accumulated other comprehensive gain/(loss)	7,401	-6,984
Total stockholders' equity	39,412,357	45,173,585
Total liabilities and stockholders' equity	$73,900,962	$80,590,808

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	225,000,000	225,000,000
Common stock, shares issued	87,227,703	87,081,862
Common stock, shares outstanding	86,004,857	85,859,016
Treasury stock, at cost	1,222,846	1,222,846

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
REVENUES:	'	'	'	'
Royalties	$1,823,935	$805,312	$3,112,183	$1,469,712
Research and development, net	-22,650	599,065	-26,265	806,100
License fees	3,000,000	4,000,000	3,000,000	4,000,000
Total revenues	4,801,285	5,404,377	6,085,918	6,275,812
COSTS AND EXPENSES:	'	'	'	'
Cost of royalty revenues	91,837	40,265	156,985	73,485
Research and development	3,328,976	3,166,639	6,474,906	5,795,096
General and administrative	2,925,259	2,903,669	5,752,157	5,470,791
Total costs and expenses	6,346,072	6,110,573	12,384,048	11,339,372
Loss from operations	-1,544,787	-706,196	-6,298,130	-5,063,560
OTHER INCOME/(EXPENSE):	'	'	'	'
Interest income	41,479	36,949	90,239	78,561
Interest expense	-949,730	-957,742	-1,900,706	-1,905,544
Change in fair value of warrant liability	557,253	333,141	648,876	634,401
Total other expense	-350,998	-587,652	-1,161,591	-1,192,582
Net loss	-1,895,785	-1,293,848	-7,459,721	-6,256,142
Net loss per common share (basic and diluted)	($0.02)	($0.02)	($0.09)	($0.08)
Weighted average common shares (basic and diluted)	85,963,836	81,128,475	85,940,842	80,615,412
Total comprehensive loss	($1,885,634)	($1,299,031)	($7,445,336)	($6,262,382)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($7,459,721)	($6,256,142)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	74,837	67,734
Stock-based compensation expense	1,427,265	1,576,537
Change in fair value of warrant liability	-648,876	-634,401
Non-cash interest expense on investments	69,046	163,826
Amortization of debt issuance costs	52,427	52,389
Non-cash in-kind interest accrued on Curis Royalty's debt	'	582,062
Payment-in kind interest on Curis Royalty's debt	-711,353	'
Changes in operating assets and liabilities:	'	'
Accounts receivable	-3,366,224	44,877
Prepaid expenses and other assets	131,908	-34,941
Accounts payable and accrued liabilities	395,205	133,810
Total adjustments	-2,575,765	1,951,893
Net cash used in operating activities	-10,035,486	-4,304,249
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchases of investments	-25,347,887	-27,704,396
Sales of investments	35,736,387	26,097,035
Purchases of property and equipment	-58,861	-34,957
Decrease in restricted cash	13,877	13,918
Net cash provided by/(used in) investing activities	10,343,516	-1,628,400
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from issuance of common stock under the Company's share-based compensation plans and warrant exercises	256,843	3,189,353
Payment of debt issuance costs	'	-261,475
Net cash provided by financing activities	256,843	2,927,878
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	564,873	-3,004,771
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	9,591,487	12,747,709
CASH AND CASH EQUIVALENTS, END OF PERIOD	$10,156,360	$9,742,938

Nature_of_Business

Nature of Business	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Nature of Business	'
	1	Nature of Business
	Curis, Inc. is an oncology-focused company seeking to develop novel drug candidates for the treatment of human cancers. As used throughout these consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.
	The Company conducts its research and development programs both internally and through strategic collaborations. The Company is leveraging its experience in targeting signaling pathways in seeking to develop drug candidates including CUDC-907, a dual histone deacetylase, or HDAC and phosphoinositide-3 kinase, or PI3K, inhibitor, and CUDC-427, a small molecule antagonist of the inhibitor of apoptosis, or IAP, proteins. Erivedge®, the first and only approved medicine for the treatment of advanced basal cell carcinoma, or BCC, is being commercialized by F. Hoffmann-La Roche Ltd., or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. The Company’s licensee Debiopharm is conducting the clinical development of the heat shock protein 90, or HSP90, inhibitor, Debio 0932.
	The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.
	The Company is subject to risks common to companies in the biotechnology industry as well as risk factors that are specific to the Company’s business, including, but not limited to: the Company’s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress it’s clinical development in indications other than BCC; the Company’s ability to advance and expand its research and development programs; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company’s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.à r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; dependence on key personnel; the Company’s ability to comply with regulatory requirements; and the Company’s ability to execute on its overall business strategies.
	The Company’s future operating results will largely depend on the magnitude of payments from its current and potential future corporate collaborators and the progress of drug candidates currently in its development pipeline. The results of the Company’s operations will vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: Roche and Genentech’s ability to successfully commercialize Erivedge; positive results in Genentech’s ongoing clinical trials; the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; and the Company’s ability to successfully enter into one or more material licenses or collaboration agreements for its proprietary drug candidates.
	The Company anticipates that existing cash, cash equivalents and investments at June 30, 2014 should enable it to maintain current and planned operations into 2016. The Company’s ability to continue funding its planned operations beyond this period is dependent upon, among other things, the success of its collaborations with Genentech, Debiopharm and the Leukemia & Lymphoma Society, or LLS, including its receipt of additional contingent cash payments under these collaborations; its ability to control expenses and its ability to raise additional funds through equity or debt financings, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	2	Basis of Presentation
	The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. These statements, however, are condensed and do not include all disclosures required by accounting principles generally accepted in the United States, or GAAP, for complete financial statements and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, or the Annual Report, as filed with the Securities and Exchange Commission on March 13, 2014.
	In the opinion of the Company, the unaudited financial statements contain all adjustments (all of which were considered normal and recurring) necessary for a fair statement of the Company’s financial position at June 30, 2014, the results of operations and cash flows for the three- and six-month periods ended June 30, 2014 and 2013 and the cash flows for the six-month periods ended June 30, 2014 and 2013.
	The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements; the estimated repayment term of the Company’s debt and related short- and long-term classification; the fair value of the Company’s debt; the collectability of receivables; the carrying value of property and equipment and intangible assets; the assumptions used in the Company’s valuation of stock-based compensation and the value of certain investments and liabilities, including our long-term warrant liability. Actual results may differ from such estimates.
	These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.

Revenue_Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Revenue Recognition	'
	3	Revenue Recognition
	The Company’s business strategy includes entering into collaborative license and development agreements with biotechnology and pharmaceutical companies for the development and commercialization of the Company’s product candidates. The terms of these agreements may provide for the Company’s licensees and collaborators to agree to make non-refundable license fee payments, research and development funding payments, contingent cash payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales if any products are successfully commercialized. For a complete discussion of the Company’s revenue recognition policy, see Note 2(c) included in its 2013 Annual Report on Form 10-K.

Collaboration_Agreements

Collaboration Agreements	6 Months Ended
	Jun. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Collaboration Agreements	'
	4		Collaboration Agreements
		(a)	Genentech June 2003 Collaboration
	In June 2003, the Company licensed its proprietary Hedgehog pathway technologies to Genentech for human therapeutic use. The primary focus of the collaborative research plan has been to develop and commercialize molecules that inhibit the Hedgehog pathway for the treatment of various cancers. The collaboration is currently focused on the development of Erivedge, which is being commercialized by Genentech in the United States and by Roche in several other countries for the treatment of advanced basal cell carcinoma. Genentech’s parent company, Roche, is also conducting additional exploratory phase 2 studies in patients with less severe forms of basal cell carcinoma. Roche is also conducting a phase 1b/2 clinical trial to investigate the safety and efficacy of Erivedge in patients with relapsed/ refractory acute myelogenous leukemia, or AML, and relapsed/refractory high-risk myelodysplastic syndrome, or MDS. There are several additional ongoing clinical trials being conducted by third parties under collaboration agreements between Genentech and the National Cancer Institute as well as Genentech and other third-party investigators.
	The Company is eligible to receive up to an aggregate of $115,000,000 in contingent cash milestone payments, exclusive of royalty payments, under the collaboration for the development of Erivedge or another small molecule Hedgehog pathway inhibitor, assuming the successful achievement by Genentech and Roche of specified clinical development and regulatory objectives. Of this aggregate amount, the Company has earned $59,000,000 as of June 30, 2014. In June 2014, Roche filed an investigational new drug application for the use of Erivedge in patients with idiopathic pulmonary fibrosis, a non-oncology indication, resulting in a milestone payment of $3,000,000 to the Company. In May 2013, Australia’s Therapeutic Goods Administration approved the sale of Erivedge in Australia resulting in a milestone payment of $4,000,000. Accordingly, the Company recognized milestone payments of $3,000,000 in the three and six months ended June 30, 2014, and $4,000,000 in the three and six months ended June 30, 2013 as license revenue in its Condensed Consolidated Statement of Operations and Comprehensive Loss as the Company does not have any further substantive performance obligations under the collaboration. At June 30, 2014, the $3,000,000 milestone was included in accounts receivable in the Company’s Condensed Consolidated Balance Sheets, and was subsequently received in July 2014.
	Pursuant to agreements by and between the Company and two university licensors, the Company has made certain payments to such licensors in connection with its receipt of milestone payments from Genentech. The Company recorded research and development expenses of $150,000 during the three and six months ended June 30, 2014, and research and development expenses of $200,000 during the three and six months ended June 30, 2013, respectively, related to payments the Company made to its licensors upon the Company’s receipt of the respective milestone payments from Genentech.
	In addition to these payments, the Company’s wholly-owned subsidiary, Curis Royalty, is entitled to a royalty on net sales of Erivedge that ranges from 5% to high single digits based upon global Erivedge sales by Roche and Genentech, subject to reduction under specified circumstances. Future royalty payments related to Erivedge will service the outstanding debt and accrued interest to BioPharma-II, up to the quarterly caps for 2014 and 2015, and until the debt is fully repaid thereafter (see Note 7). The Company recognized royalty revenues from Genentech’s net sales of Erivedge of $1,823,935 and $805,312 during the three months ended June 30, 2014 and 2013, respectively, and $3,112,183 and $1,469,712 during the six months ended June 30, 2014 and 2013, respectively. The Company recorded cost of royalty revenues within the costs and expenses section of its Condensed Consolidated Statements of Operations and Comprehensive Loss of $91,837 and $40,265 during the three months ended June 30, 2014 and 2013, respectively, and $156,985 and $73,485 during the six months ended June 30, 2014 and 2013, respectively. For each of these periods, the cost of royalty revenue amounts are comprised of 5% of the Erivedge royalties earned by the Company that it is obligated to pay to university licensors. As further discussed in Note 7, the Company expects that all royalty revenues received by Curis Royalty from Genentech on net sales of Erivedge will be used by Curis Royalty to pay principal and interest under the loan that Curis Royalty received from BioPharma II, subject to specified quarterly caps, until such time as the loan is fully repaid.
	The Company recorded research and development revenue of $31,376 and $46,653 during the three months ended June 30, 2014 and 2013, respectively, and research and development revenue of $71,237 and $93,994 during the six months ended June 30, 2014 and 2013, respectively, related to expenses incurred by the Company on behalf of Genentech that were paid by the Company and for which Genentech is obligated to reimburse the Company. During the three and six months ended June 30, 2014, Genentech incurred expenses of $54,153 and $139,583, respectively, under this collaboration which the Company is obligated to reimburse to Genentech, and which the Company has recorded as contra-revenues in its Condensed Consolidated Statements of Operations and Comprehensive Loss.
		(b)	The Leukemia & Lymphoma Society Agreement
	In November 2011, the Company entered into an agreement under which The Leukemia & Lymphoma Society (LLS) agreed to support the Company’s ongoing development of CUDC-907 for patients with relapsed or refractory lymphoma and multiple myeloma. Under the agreement, LLS has agreed to make milestone payments up to $4,000,000 that are contingent upon the Company’s achievement of specified clinical development objectives with CUDC-907. The Company earned milestone payments under the LLS agreement totaling $550,000 and $650,000 during the three and six-month periods ended June 30, 2013, respectively, related to the progress of the ongoing phase I clinical trial of CUDC-907. Since the inception of the agreement, the Company has received $1,650,000 from LLS related to milestones achieved under this agreement. Additional milestone payments may be earned assuming CUDC-907 continues to progress through the ongoing phase I clinical trial.
	In January 2013, the Company earned a milestone payment under the LLS agreement of $100,000 related to treatment of the first patient in the phase I clinical trial of CUDC-907. The Company applied the provisions of ASC 605-28, Revenue Recognition, Milestone Method to determine whether the revenue earned under this agreement should be accounted for as substantive milestones. In determining whether the milestones in this arrangement are substantive, the Company considered whether uncertainty exists as to: (i) the achievement of the milestone event at the inception of the arrangement; (ii) whether the achievement of the milestone involves substantive effort and can only be achieved based in whole or part on the performance or the occurrence of a specific outcome resulting from the Company’s performance; (iii) whether the amount of the milestone payment appears reasonable either in relation to the effort expected to be expended or to the projected enhancement of the value of the delivered items; (iv) whether there is any future performance required to earn the milestone; and (v) whether the consideration is reasonable relative to all deliverables and payment terms in the arrangement. When a substantive milestone is achieved, the accounting guidance permits recognition of revenue related to the milestone payment in its entirety. The Company determined that the milestones achieved in the first half of 2013 under the LLS agreement were substantive and recorded the related revenue of $550,000 and $650,000 during the three and six month periods ended June 30, 2013, respectively. The Company did not receive any milestone payments pursuant to the LLS agreement during the three or six months ended June 30, 2014.
	Under certain conditions associated with the Company’s successful partnering and/or commercialization of CUDC-907 in the specified indications, the Company may be obligated to make payments, including royalties, to LLS of up to $10,000,000. This obligation is capped at 2.5 times the amount the Company receives from LLS, and, as of June 30, 2014, the maximum obligation, assuming that specified events occur, such as CUDC-907 successfully progressing through future clinical trials or the Company’s entry into a collaboration related to CUDC-907 would be $4,125,000. If CUDC-907 does not continue to meet its clinical safety endpoints in future clinical trials in the defined field or fails to obtain necessary regulatory approvals, all funding provided to the Company by LLS will be considered a non-refundable grant. As of June 30, 2014, the Company has not recorded an obligation to repay any of the funds received from LLS because the contingent repayment obligation depends solely on the successful results of the continued development of CUDC-907, which is not probable at June 30, 2014 as this program remains in the early stages of clinical development.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	5	Fair Value Measurements
	The Company discloses fair value measurements based on a framework outlined by GAAP which requires expanded disclosures regarding fair value measurements. GAAP also defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact.
	The FASB Codification Topic 820, Fair Value Measurements and Disclosures, requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets and liabilities. The income approach uses valuation techniques to convert future amounts, such as cash flows or earnings, to a single present amount on a discounted basis. The cost approach is based on the amount that currently would be required to replace the service capacity of an asset (replacement cost). Valuation techniques should be consistently applied. GAAP also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1	Quoted prices in active markets for identical assets or liabilities.
	Level 2	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s warrant liability was valued using a probability-weighted Black-Scholes model, discussed further in Note 8, and is therefore classified as Level 3.
	In accordance with the fair value hierarchy, the following table shows the fair value as of June 30, 2014 and December 31, 2013 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the valuation techniques the Company used to determine their fair value. No financial assets or liabilities are measured at fair value on a nonrecurring basis at June 30, 2014 and December 31, 2013.
		Quoted Prices in			Other Observable		Unobservable		Fair Value
		Active Markets			Inputs		Inputs (Level 3)
		(Level 1)			(Level 2)
	As of June 30, 2014:
	Cash equivalents
	Money market funds	$	6,761,408		$	—	$	—	$	6,761,408
	Corporate commercial paper		—			1,544,985		—		1,544,985
	Municipal bonds		—			1,100,000		—		1,100,000
	Short- and long-term investments
	Corporate commercial paper, stock, bonds and notes		20,316,638			27,552,160		—		47,868,798
	Total assets at fair value	$	27,078,046		$	30,197,145	$	—	$	57,275,191
	Warrant liability		—			—		67,910		67,910
	Total liabilities at fair value	$	—		$	—	$	67,910	$	67,910
		Quoted Prices in			Other Observable		Unobservable		Fair Value
		Active Markets			Inputs (Level 2)		Inputs (Level 3)
		(Level 1)
	As of December 31, 2013:
	Cash equivalents
	Money market funds	$	5,535,716		$	—	$	—	$	5,535,716
	Corporate commercial paper, bonds and notes		—			1,749,983		—		1,749,983
	Municipal bonds		—			1,110,000		—		1,110,000
	Short- and long-term investments
	US government obligations		—			1,151,932		—		1,151,932
	Corporate commercial paper, stock, bonds and notes		20,176,154			36,984,932		—		57,161,086
	Total assets at fair value	$	25,711,870		$	40,996,847	$	—	$	66,708,717
	Warrant liability		—			—		716,786		716,786
	Total liabilities at fair value	$	—		$	—	$	716,786	$	716,786
	The above tables exclude a certificate of deposit in the amounts of $1,002,861 and $1,001,802 that the Company held as of June 30, 2014 and December 31, 2013, respectively.
	The following table rolls forward the fair value of the Company’s warrant liability, the fair value of which is determined by Level 3 inputs for the six months ended June 30, 2014 and 2013:
	Balance at December 31, 2013	$	716,786
	Change in fair value for the six months ended June 30, 2014		(648,876	)
	Balance at June 30, 2014	$	67,910
	Balance at December 31, 2012	$	1,488,179
	Change in fair value for the six months ended June 30, 2013		(634,401	)
	Balance at June 30, 2013	$	853,778

Investments

Investments	6 Months Ended
	Jun. 30, 2014
Investments Debt And Equity Securities [Abstract]	'
Investments	'
	6	Investments
	The amortized cost, unrealized losses and fair value of short-term investments available-for-sale as of June 30, 2014 with maturity dates ranging between one and twelve months and with a weighted average maturity of 6.0 months are as follows:
		Amortized		Unrealized		Unrealized			Fair Value
		Cost		Gain		Loss
	Corporate bonds and notes	$	44,604,196	$	14,547	$	(7,153	)	$	44,611,590
	Total investments	$	44,604,196	$	14,547	$	(7,153	)	$	44,611,590
	In addition, a certificate of deposit in the amount of $1,002,861 that the Company held as of June 30, 2014 was included within short-term investments in the consolidated balance sheet but is excluded from the table above as it was not deemed to be a security.
	As of June 30, 2014, the Company also recorded long-term investments of $3,257,209 on its Consolidated Balance Sheet. This amount is comprised of corporate and government-secured debt securities with maturities ranging from July 2015 to November 2015 with a weighted average maturity of 14.6 months and with amortized cost totaling $3,257,489, less unrealized net losses of $280.
	The amortized cost, unrealized losses and fair value of short-term investments available-for-sale as of December 31, 2013 with maturity dates ranging between one and twelve months and with a weighted average maturity of 4.7 months are as follows:
		Amortized		Unrealized		Unrealized			Fair Value
		Cost		Gain		Loss
	Corporate bonds and notes	$	47,091,593	$	9,036	$	(15,476	)	$	47,085,153
	US government and municipal obligations		501,170		10		—			501,180
	Total investments	$	47,592,763	$	9,046	$	(15,476	)	$	47,586,333
	In addition, a certificate of deposit in the amount of $1,001,802 that the Company held as of December 31, 2013 was included within short-term investments in the consolidated balance sheet but is excluded from the table above as it was not deemed to be a security.
	As of December 31, 2013, the Company also recorded long-term investments of $10,726,685 on its Consolidated Balance Sheet. This amount is comprised of corporate and government-secured debt securities with maturities ranging from January 2015 to May 2015 with a weighted average maturity of 14.3 months and with amortized cost totaling $10,727,958, less unrealized net losses of $1,273.

Debt

Debt	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	7	Debt
	In December 2012, Curis’ wholly-owned subsidiary, Curis Royalty, received a $30,000,000 loan at an annual interest rate of 12.25% pursuant to a credit agreement between Curis Royalty and BioPharma-II. In connection with the loan, Curis transferred to Curis Royalty its right to receive certain future royalty and royalty-related payments on the commercial sales of Erivedge that it may receive from Genentech. The loan and accrued interest will be repaid by Curis Royalty using such royalty and royalty-related payments. To secure repayment of the loan, Curis Royalty granted a first priority lien and security interest (subject only to permitted liens) to BioPharma-II in all of its assets and all real, intangible and personal property, including all of its right, title and interest in and to the royalty and royalty-related payments. The loan constitutes an obligation of Curis Royalty, and is intended to be non-recourse to Curis. Under the terms of the loan, quarterly royalty payments received by Curis Royalty from Genentech will first be applied to pay (i) escrow fees payable by Curis pursuant to an escrow agreement between Curis, Curis Royalty, BioPharma-II and Boston Private Bank and Trust Company, (ii) Curis’ royalty obligations to academic institutions, (iii) certain expenses incurred by BioPharma-II in connection with the credit agreement and related transaction documents, including enforcement of its rights in the case of an event of default under the credit agreement and (iv) expenses incurred by Curis enforcing its right to indemnification under the collaboration agreement with Genentech. Remaining amounts, subject to caps of $2,000,000 per quarter in 2014 and $3,000,000 per quarter in 2015, will be applied first to pay interest and second, principal on the loan. Curis Royalty will be entitled to receive the remaining royalty amounts above the caps, if any, and Curis remains entitled to receive any contingent payments upon achievement of clinical development objectives. Curis Royalty retains its right to royalty payments related to sales of Erivedge following repayment of the loan.
	The final maturity date of the loan will be the earlier of the date when the principal is paid in full and the termination of Curis Royalty’s right to receive royalties under the collaboration agreement with Genentech. At any time after January 1, 2017, Curis Royalty may, subject to certain limitations, prepay the outstanding principal of the loan in whole or in part, at a price equal to 105% of the outstanding principal on the loan, plus accrued but unpaid interest. The obligations of Curis Royalty under the credit agreement to repay the loan may be accelerated upon the occurrence of an event of default as defined in the credit agreement.
	During the six month ended June 30, 2014, the Company made payments totaling $2,546,417, of which $1,835,064 related to the payment of accrued interest and $711,353 related to payment of the previously capitalized interest. As of June 30, 2014, the Company recorded short- and long-term debt of $5,498,670 and $24,372,065, respectively (net of unamortized issuance costs of $53,529 and $78,351, respectively), and at December 31, 2013, the Company recorded short- and long-term debt of $2,610,174 and $27,945,186, respectively (net of unamortized issuance costs of $53,503 and $105,105, respectively), related to the loan, with such amounts recorded within the Company’s Consolidated Balance Sheets. In addition, the Company recorded accrued interest on the debt of $312,150 and $298,935 as of June 30, 2014 and December 31, 2013, respectively, with such amounts included in the Company’s accrued liabilities section of its Consolidated Balance Sheets. Because the repayment of the term loan is contingent upon the level of Erivedge royalties received, the repayment term may be shortened or extended depending on the actual level of Erivedge royalties. In addition, if Erivedge royalties are insufficient to pay the accrued interest on the outstanding loan, the unpaid interest outstanding will be added to the principal on a quarterly basis. Currently, Curis management estimates that the loan will be repaid in the first half of 2017, but this estimate could be adversely affected and the repayment period could be extended if its royalties are less than it currently anticipates.
	At June 30, 2014, the fair value of the principal portion of the debt is estimated as $30,490,000. Due to the assumptions required in estimating future Erivedge royalties, the expected repayment period and weighting of various royalty projection scenarios, determining the fair value of the debt required application of Level 3 inputs.
	The Company incurred debt issuance costs totaling $421,715 in connection with this loan transaction, of which $215,000 related to expenses that the Company paid on behalf of BioPharma-II and the remaining $206,715 were incurred directly by the Company. The debt issuance costs incurred directly by the Company were capitalized as assets and those costs paid on behalf of BioPharma-II have been netted against the debt and accrued interest in the Company’s Condensed Consolidated Balance Sheets as of June 30, 2014 and December 31, 2013 as detailed in the following table:
		As of
		June 30, 2014			December 31, 2013
	Other current assets	$	51,466		$	51,441
	Other assets		75,331			101,055
	Total debt issuance costs		126,797			152,496
	Debt, current		5,552,199			2,663,677
	Debt issue costs, current		(53,529	)		(53,503	)
	Debt, current portion net of issuance costs	$	5,498,670		$	2,610,174
	Debt, long-term		24,450,416			28,050,291
	Debt issue costs, long-term		(78,351	)		(105,105	)
	Debt, net of current portion and issuance costs	$	24,372,065		$	27,945,186
	All issuance costs are being amortized over the estimated term of the debt using the straight-line method which approximates the effective interest method. For the three and six months ended June 30, 2014, the Company recognized interest expense related to the loan with BioPharma-II of $949,730 and $1,900,706, respectively. For the three and six months ended June 30, 2013, the Company recognized interest expense related to the loan with BioPharma-II of $957,742 and $1,905,544, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires management to make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized.

Common_Stock_and_Warrant_Liabi

Common Stock and Warrant Liability	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Common Stock and Warrant Liability	'
	8		Common Stock and Warrant Liability
		(a)	Warrant Liability
	On January 27, 2010, the Company completed a registered direct offering of 6,449,288 units with each unit consisting of (i) one share of the Company’s common stock and (ii) one warrant to purchase 0.25 of one share of common stock at a purchase price of $2.52 per unit. The Company received net proceeds from the sale of the units, after deducting offering expenses, of approximately $14,942,000.
	In connection with this offering, the Company issued warrants to purchase an aggregate of 1,612,322 shares of common stock. As of June 30, 2014, warrants to purchase 238,805 shares of the Company’s common stock have been exercised and warrants to purchase 1,373,517 shares of common stock remain outstanding. The warrants have an initial exercise price of $3.55 per share and expire in January 2015. The warrants contain anti-dilution adjustment provisions that will result in a decrease in the price and an increase in the number of shares of common stock issuable upon exercise of such warrants in the event of certain issuances of common stock by the Company at prices below $3.55 per share.
	Due to the warrant terms, the warrants are deemed to be a liability and, therefore, the fair value of the warrants was recorded as a short-term liability as of June 30, 2014 and a long-term liability as of December 31, 2013 in the Consolidated Balance Sheets. The Company has estimated the fair value of the warrants using a Black-Scholes option pricing model with updated assumptions at each reporting date as detailed in the following table:
			As of June 30,
			2014			2013
	Fair value of the warrants		$	67,910		$	853,778
	Expected term			0.6 years			1.6 years
	Risk-free interest rate			0.06	%		0.25	%
	Volatility			63	%		47.2	%
	Dividends			None			None
	The warrants are revalued at each reporting period and the resulting change in fair value of the warrant liability will be recognized in the Consolidated Statement of Operations and Comprehensive Loss. The Company recorded other income of $557,253 and $333,141 for the three months ended June 30, 2014 and 2013, respectively, and other income of $648,876 and $634,401 for the six months ended June 30, 2014 and 2013, respectively, as a result of a change in the fair value of the warrant liability that was primarily due to decreases in the remaining term and the Company’s common stock price during the respective reporting periods.
		(b)	Stock Option Exercises Paid with Company Common Stock
	The Company’s 2000 Stock Incentive Plan and the Amended and Restated 2010 Plan generally allows participants to purchase common stock upon the exercise of a stock option by delivery of shares of Company common stock held directly by the participant, with such shares of common stock valued at the closing price on NASDAQ on the date of exercise. During the three months ended June 30, 2013, the Chief Executive Officer, the Chief Financial Officer and one member of the Company’s board of directors exercised stock options by remitting shares of Curis common stock held by the respective executive officer or director to the Company. The Company accounted for the value of the common stock remitted to the Company in satisfaction of the exercise price as treasury stock under the cost method. These option holders remitted an aggregate of 175,139 shares during the three months ended June 30, 2013 with an aggregate value equal to $632,755. The company had no such transactions during the three or six months ended June 30, 2014.

Accrued_Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2014
Other Liabilities Disclosure [Abstract]	'
Accrued Liabilities	'
	9	Accrued Liabilities
	Accrued liabilities consist of the following:
		June 30,		December 31,
		2014		2013
	Accrued compensation	$	811,916	$	1,267,954
	Professional fees		219,450		166,200
	Accrued interest on debt (see Note 7)		312,150		298,935
	Other		166,116		178,390
	Total	$	1,509,632	$	1,911,479

Accounting_for_StockBased_Comp

Accounting for Stock-Based Compensation	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Accounting for Stock-Based Compensation	'
	10	Accounting for Stock-Based Compensation
	As of June 30, 2014, the Company had two shareholder-approved, share-based compensation plans: (i) the Amended and Restated 2010 Stock Incentive Plan, or the 2010 Plan, adopted by the Board of Directors in March 2013 and approved by shareholders in May 2013 and (ii) the 2010 Employee Stock Purchase Plan, or the ESPP, adopted by the Board of Directors in April 2010 and approved by shareholders in June 2010. For a complete discussion of the Company’s share-based compensation plans, see Note 4, “Stock Plans and Stock Based Compensation” in the notes to the Company’s consolidated financial statements included in Item 8 of Part II of the Company’s Annual Report.
	During six months ended June 30, 2014, the Company’s board of directors granted options to purchase 1,987,500 shares of the Company’s common stock to officers and employees of the Company under the 2010 Plan. Of this amount, options to purchase 947,500 shares of common stock vest over a four-year period and bear exercise prices that are equal to the closing market price of the Company’s common stock on the NASDAQ Global Market on the grant dates. The remaining options to purchase 1,040,000 shares of common stock were issued to the Company’s officers and will vest in tranches only if the closing sale price of the Company’s common stock is maintained at specified levels for a period of 60 consecutive trading days prior to the third anniversary of the respective grant dates. If the specified market conditions are not achieved prior to the third anniversary of the respective grant dates, any unvested options will be forfeited and shall again be available for grant under the 2010 Plan.
	During the six months ended June 30, 2014, the Company’s board of directors also granted options to its non-employee directors to purchase 235,000 shares of common stock under the 2010 Plan, which will vest monthly over a one-year period. All options granted to non-employee directors during the six months ended June 30, 2014 bear exercise prices that are equal to the closing market price of the Company’s common stock on the NASDAQ Global Market on the grant date.
	Employee and Director Grants
	Vesting Tied to Service Conditions
	In determining the fair value of stock options, the Company generally uses the Black-Scholes option pricing model. As discussed below, for employee stock options with market conditions, the Company uses a Monte Carlo simulation valuation model. The Black-Scholes option pricing model employs the following key assumptions for employee and director options awarded during the six months ended June 30, 2014 and 2013 based on the assumptions noted in the following table:
		Six Months Ended
		June 30,
		2014		2013
	Expected life (years) – employees	6		6
	Expected life (years) – officers and directors	7		7
	Risk-free interest rate	1.85-2.2%		1.0-1.6%
	Volatility	70-71%		70-72%
	Dividends	None		None
	The expected volatility is based on the annualized daily historical volatility of the Company’s stock price for a time period consistent with the expected term of each grant. Management believes that the historical volatility of the Company’s stock price best represents the volatility of the stock price. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the respective grant. The Company has not historically paid cash dividends, and does not expect to pay cash dividends in the foreseeable future.
	The stock price volatility and expected terms utilized in the calculation involve management’s best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. GAAP also requires that the Company recognize compensation expense for only the portion of options that are expected to vest. Therefore, management calculated an estimated annual pre-vesting forfeiture rate that is derived from historical employee termination behavior since the inception of the Company, as adjusted. If the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required in future periods.
	The aggregate intrinsic value of employee options outstanding at June 30, 2014 was $1,906,000, of which $1,837,000 related to exercisable options. The weighted average grant-date fair values of stock options granted during the six months ended June 30, 2014 and 2013 were $1.82 and $2.14, respectively. As of June 30, 2014, there was approximately $6,192,000, net of the impact of estimated forfeitures, of unrecognized compensation cost related to unvested employee stock option awards outstanding under the Company’s 2000 Stock Incentive Plan and the Amended and Restated 2010 Plan that is expected to be recognized as expense over a weighted average period of 2.80 years. The intrinsic values of employee stock options exercised during the six months ended June 30, 2014 and 2013 were $105,000 and $1,598,000, respectively.
	Vesting Tied to Market Conditions
	Monte Carlo simulation models were used to value stock options to purchase an aggregate of 1,040,000 shares of common stock granted to the Company’s officers during the six months ended June 30, 2014. Of this amount, options to purchase 640,000 shares of common stock were granted in February 2014 with an exercise price of $3.09 and options to purchase 400,000 shares of common stock were granted in June 2014 with an exercise price of $1.75 per share that contained specific market conditions. The key assumptions used in these Monte Carlo simulation models and resulting valuations are noted in the following table:
		Market Condition			Market Condition
		Options Granted			Options Granted
		February 18, 2014			June 2, 2014
	Expected life (years) – officers		6			6
	Risk-free interest rate		1.9	%		2.1	%
	Volatility		70	%		65	%
	Dividends		None			None
	Number of options granted		640,000			400,000
	Fair value per share	$	1.2		$	0.34
	Based on the above, the Monte Carlo simulation models calculated aggregate fair value of $905,000, excluding forfeitures, related to these grants that will be recognized on a straight-line basis over the estimated vesting periods of the separate tranches. These awards accounted for $108,366 and $156,377 of the employee stock-based compensation expense recorded by the Company for the three and six months ended June 30, 2014.
	Employee Stock-Based Compensation Expense
	The Company recorded $794,255 and $1,482,027 in compensation expense for the three and six months ended June 30, 2014, respectively, and $751,702 and $1,396,027 in compensation expense for the three and six months ended June 30, 2013, respectively, related to employee and director stock option grants. The total fair values of vested stock options for the six months ended June 30, 2014 and 2013 were $1,376,000 and $1,808,000, respectively.
	Non-Employee Grants
	The Company has periodically granted stock options and unrestricted stock awards to consultants for services, pursuant to the Company’s stock plans at the fair market value on the respective dates of grant. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would also be cancelled. The Company reversed expense related to non-employee stock options of $110,434 and $54,762, for the three and six months ended June 30, 2014, respectively, and expense of $164,269 and $180,510 for the three and six months ended June 30, 2013, respectively.
	Total Stock-Based Compensation Expense
	For the three and six months ended June 30, 2014 and 2013, the Company recorded employee and non-employee stock-based compensation expense to the following line items in its Costs and Expenses section of the Consolidated Statements of Operations and Comprehensive Loss, including expense related to its ESPP:
		For the Three Months Ended						For the Six Months Ended
		June 30,						June 30,
		2014			2013			2014		2013
	Research and development expenses	$	108,803		$	289,640		$	300,748	$	496,519
	General and administrative expenses		575,018			626,331			1,126,517		1,080,018
	Total stock-based compensation expense	$	683,821		$	915,971		$	1,427,265	$	1,576,537

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Accumulated Other Comprehensive Income (Loss)	'
	11	Accumulated Other Comprehensive Income (Loss)
	The following table summarizes the changes in accumulated other comprehensive income (loss) as of June 30, 2014:
		Unrealized Losses on
		Securities  Available-for-Sale
	Balance, as of December 31, 2013	$	(6,984	)
	Other comprehensive gain before reclassifications		14,385
	Amounts reclassified from accumulated other comprehensive income (loss)		—
	Net current period other comprehensive loss		14,385
	Balance, as of June 30, 2014	$	7,401
	The above amounts do not reflect a tax effect as the Company expects to record a net loss for 2014.

Loss_Per_Common_Share

Loss Per Common Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Loss Per Common Share	'
	12	Loss Per Common Share
	The Company applies ASC Topic 260—Earnings per Share, which establishes standards for computing and presenting earnings per share. Basic and diluted loss per common share is computed using the weighted-average number of shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common share for the three and six months ended June 30, 2014 and 2013, as the effect of the potential common stock equivalents is antidilutive due to the Company’s net loss position for these periods. Antidilutive securities consist of stock options and warrants outstanding as of the respective reporting period as follows:
		For the Three and Six Months Ended		For the Three and Six Months Ended
		June 30,		June 30,
		2014		2013
	Stock options outstanding		11,389,869		10,663,319
	Warrants outstanding		1,373,517		1,373,517
	Total antidilutive securities		12,763,386		12,036,836

Related_Party_Transaction

Related Party Transaction	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transaction	'
	13	Related Party Transaction
	On June 2, 2014, Daniel R. Passeri resigned as Chief Executive Officer of the Company. Mr. Passeri will continue to serve as a Class II director of the Company. On June 2, 2014, the Board of Directors of the Company elected Mr. Passeri Vice Chairman of the Board. As a non-employee director, Mr. Passeri will be compensated $100,000 per year plus meeting fees for his participation on the Company’s board.
	The Company and Mr. Passeri entered into a consulting agreement on June 2, 2014. The agreement is for an initial term of one year, subject to renewal or earlier termination by the parties. Pursuant to the terms of the consulting agreement, Mr. Passeri has agreed to provide 120 hours per month of consulting services to the Company on intellectual property, corporate and strategic matters. In consideration for the services rendered by Mr. Passeri to the Company, the Company has agreed to pay Mr. Passeri $32,500 per month until June 1, 2015, provided that if at any time during the consultation period Mr. Passeri obtains full time employment with a third party, then Mr. Passeri and the Company will negotiate a good faith reduction in the number of hours that Mr. Passeri will consult, and thereafter Mr. Passeri will be paid an hourly fee, in lieu of the monthly retainer, for services rendered under the consulting agreement. From June 2, 2014 until June 1, 2015, the consulting agreement may be terminated at any time by mutual agreement between the parties. If the parties renew the agreement, then after June 1, 2015, Mr. Passeri will receive $30,000 per month during the renewal period and either party may terminate the consulting agreement by providing thirty days’ written notice to the other party. In addition, if the parties cannot agree on a revised hourly commitment in connection with Mr. Passeri obtaining full time employment with a third party, then either party will have the right to terminate the agreement immediately. The Company may terminate the consulting agreement immediately if Mr. Passeri breaches, or threatens to breach the terms of the non-disclosure and non-competition agreement previously entered into with the Company. Pursuant to the terms of the consulting agreement, the Company recognized expenses of $30,333 during the three and six months ended June 30, 2014 under this consulting agreement.

Recently_Issued_Accounting_Pro

Recently Issued Accounting Pronouncements	6 Months Ended
	Jun. 30, 2014
Accounting Changes And Error Corrections [Abstract]	'
Recently Issued Accounting Pronouncements	'
	14	Recently Issued Accounting Pronouncements
	In May 2014, the FASB issued guidance codified in ASC 606, Revenue Recognition—Revenue from Contracts with Customers , which amends the guidance in former ASC 605, Revenue Recognition, and is effective for public companies for fiscal years beginning after December 15, 2016. The Company is currently evaluating the impact of the provisions of ASC 606.

Collaboration_Agreements_Polic

Collaboration Agreements (Policies)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Revenue Recognition	'
	The Company applied the provisions of ASC 605-28, Revenue Recognition, Milestone Method to determine whether the revenue earned under this agreement should be accounted for as substantive milestones. In determining whether the milestones in this arrangement are substantive, the Company considered whether uncertainty exists as to: (i) the achievement of the milestone event at the inception of the arrangement; (ii) whether the achievement of the milestone involves substantive effort and can only be achieved based in whole or part on the performance or the occurrence of a specific outcome resulting from the Company’s performance; (iii) whether the amount of the milestone payment appears reasonable either in relation to the effort expected to be expended or to the projected enhancement of the value of the delivered items; (iv) whether there is any future performance required to earn the milestone; and (v) whether the consideration is reasonable relative to all deliverables and payment terms in the arrangement. When a substantive milestone is achieved, the accounting guidance permits recognition of revenue related to the milestone payment in its entirety. The Company determined that the milestones achieved in the first half of 2013 under the LLS agreement were substantive and recorded the related revenue of $550,000 and $650,000 during the three and six month periods ended June 30, 2013, respectively. The Company did not receive any milestone payments pursuant to the LLS agreement during the three or six months ended June 30, 2014.
Fair Value Measurements and Disclosures	'
	The FASB Codification Topic 820, Fair Value Measurements and Disclosures, requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets and liabilities. The income approach uses valuation techniques to convert future amounts, such as cash flows or earnings, to a single present amount on a discounted basis. The cost approach is based on the amount that currently would be required to replace the service capacity of an asset (replacement cost). Valuation techniques should be consistently applied. GAAP also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1	Quoted prices in active markets for identical assets or liabilities.
	Level 2	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s warrant liability was valued using a probability-weighted Black-Scholes model, discussed further in Note 8, and is therefore classified as Level 3.
Earnings Per Share	'
	The Company applies ASC Topic 260—Earnings per Share, which establishes standards for computing and presenting earnings per share. Basic and diluted loss per common share is computed using the weighted-average number of shares outstanding during the period.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Financial Assets or Liabilities Measured at Fair Value on Recurring Basis	'
	In accordance with the fair value hierarchy, the following table shows the fair value as of June 30, 2014 and December 31, 2013 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the valuation techniques the Company used to determine their fair value. No financial assets or liabilities are measured at fair value on a nonrecurring basis at June 30, 2014 and December 31, 2013.
		Quoted Prices in			Other Observable		Unobservable		Fair Value
		Active Markets			Inputs		Inputs (Level 3)
		(Level 1)			(Level 2)
	As of June 30, 2014:
	Cash equivalents
	Money market funds	$	6,761,408		$	—	$	—	$	6,761,408
	Corporate commercial paper		—			1,544,985		—		1,544,985
	Municipal bonds		—			1,100,000		—		1,100,000
	Short- and long-term investments
	Corporate commercial paper, stock, bonds and notes		20,316,638			27,552,160		—		47,868,798
	Total assets at fair value	$	27,078,046		$	30,197,145	$	—	$	57,275,191
	Warrant liability		—			—		67,910		67,910
	Total liabilities at fair value	$	—		$	—	$	67,910	$	67,910
		Quoted Prices in			Other Observable		Unobservable		Fair Value
		Active Markets			Inputs (Level 2)		Inputs (Level 3)
		(Level 1)
	As of December 31, 2013:
	Cash equivalents
	Money market funds	$	5,535,716		$	—	$	—	$	5,535,716
	Corporate commercial paper, bonds and notes		—			1,749,983		—		1,749,983
	Municipal bonds		—			1,110,000		—		1,110,000
	Short- and long-term investments
	US government obligations		—			1,151,932		—		1,151,932
	Corporate commercial paper, stock, bonds and notes		20,176,154			36,984,932		—		57,161,086
	Total assets at fair value	$	25,711,870		$	40,996,847	$	—	$	66,708,717
	Warrant liability		—			—		716,786		716,786
	Total liabilities at fair value	$	—		$	—	$	716,786	$	716,786
Fair Value of Warrant Liability	'
	The following table rolls forward the fair value of the Company’s warrant liability, the fair value of which is determined by Level 3 inputs for the six months ended June 30, 2014 and 2013:
	Balance at December 31, 2013	$	716,786
	Change in fair value for the six months ended June 30, 2014		(648,876	)
	Balance at June 30, 2014	$	67,910
	Balance at December 31, 2012	$	1,488,179
	Change in fair value for the six months ended June 30, 2013		(634,401	)
	Balance at June 30, 2013	$	853,778

Investments_Tables

Investments (Tables)	6 Months Ended
	Jun. 30, 2014
Investments Debt And Equity Securities [Abstract]	'
Summary of Amortized Cost, Unrealized Gains and Fair Value of Short-term Investments	'
	The amortized cost, unrealized losses and fair value of short-term investments available-for-sale as of June 30, 2014 with maturity dates ranging between one and twelve months and with a weighted average maturity of 6.0 months are as follows:
		Amortized		Unrealized		Unrealized			Fair Value
		Cost		Gain		Loss
	Corporate bonds and notes	$	44,604,196	$	14,547	$	(7,153	)	$	44,611,590
	Total investments	$	44,604,196	$	14,547	$	(7,153	)	$	44,611,590
	The amortized cost, unrealized losses and fair value of short-term investments available-for-sale as of December 31, 2013 with maturity dates ranging between one and twelve months and with a weighted average maturity of 4.7 months are as follows:
		Amortized		Unrealized		Unrealized			Fair Value
		Cost		Gain		Loss
	Corporate bonds and notes	$	47,091,593	$	9,036	$	(15,476	)	$	47,085,153
	US government and municipal obligations.		501,170		10		—			501,180
	Total investments	$	47,592,763	$	9,046	$	(15,476	)	$	47,586,333

Debt_Tables

Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt Issuance Costs	'
	The debt issuance costs incurred directly by the Company were capitalized as assets and those costs paid on behalf of BioPharma-II have been netted against the debt and accrued interest in the Company’s Condensed Consolidated Balance Sheets as of June 30, 2014 and December 31, 2013 as detailed in the following table:
		As of
		June 30, 2014			December 31, 2013
	Other current assets	$	51,466		$	51,441
	Other assets		75,331			101,055
	Total debt issuance costs		126,797			152,496
	Debt, current		5,552,199			2,663,677
	Debt issue costs, current		(53,529	)		(53,503	)
	Debt, current portion net of issuance costs	$	5,498,670		$	2,610,174
	Debt, long-term		24,450,416			28,050,291
	Debt issue costs, long-term		(78,351	)		(105,105	)
	Debt, net of current portion and issuance costs	$	24,372,065		$	27,945,186

Common_Stock_and_Warrant_Liabi1

Common Stock and Warrant Liability (Tables)	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Estimated Fair Value of Warrants	'
	The Company has estimated the fair value of the warrants using a Black-Scholes option pricing model with updated assumptions at each reporting date as detailed in the following table:
		As of June 30,
		2014			2013
	Fair value of the warrants	$	67,910		$	853,778
	Expected term		0.6 years			1.6 years
	Risk-free interest rate		0.06	%		0.25	%
	Volatility		63	%		47.2	%
	Dividends		None			None

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Other Liabilities Disclosure [Abstract]	'
Accrued Liabilities	'
	Accrued liabilities consist of the following:
		June 30,		December 31,
		2014		2013
	Accrued compensation	$	811,916	$	1,267,954
	Professional fees		219,450		166,200
	Accrued interest on debt (see Note 7)		312,150		298,935
	Other		166,116		178,390
	Total	$	1,509,632	$	1,911,479

Accounting_for_StockBased_Comp1

Accounting for Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Employee and Non-Employee Share Based Compensation Expense Allocation	'
	For the three and six months ended June 30, 2014 and 2013, the Company recorded employee and non-employee stock-based compensation expense to the following line items in its Costs and Expenses section of the Consolidated Statements of Operations and Comprehensive Loss, including expense related to its ESPP:
		For the Three Months Ended						For the Six Months Ended
		June 30,						June 30,
		2014			2013			2014		2013
	Research and development expenses	$	108,803		$	289,640		$	300,748	$	496,519
	General and administrative expenses		575,018			626,331			1,126,517		1,080,018
	Total stock-based compensation expense	$	683,821		$	915,971		$	1,427,265	$	1,576,537
Vesting Tied to Service Conditions [Member]	'
Valuation Assumptions Used to Calculate Fair Value of Employee Options Awarded	'
	As discussed below, for employee stock options with market conditions, the Company uses a Monte Carlo simulation valuation model. The Black-Scholes option pricing model employs the following key assumptions for employee and director options awarded during the six months ended June 30, 2014 and 2013 based on the assumptions noted in the following table:
		Six Months Ended
		June 30,
		2014		2013
	Expected life (years) – employees	6		6
	Expected life (years) – officers and directors	7		7
	Risk-free interest rate	1.85-2.2%		1.0-1.6%
	Volatility	70-71%		70-72%
	Dividends	None		None
Vesting Tied to Market Conditions [Member]	'
Valuation Assumptions Used to Calculate Fair Value of Employee Options Awarded	'
	Monte Carlo simulation models were used to value stock options to purchase an aggregate of 1,040,000 shares of common stock granted to the Company’s officers during the six months ended June 30, 2014. Of this amount, options to purchase 640,000 shares of common stock were granted in February 2014 with an exercise price of $3.09 and options to purchase 400,000 shares of common stock were granted in June 2014 with an exercise price of $1.75 per share that contained specific market conditions. The key assumptions used in these Monte Carlo simulation models and resulting valuations are noted in the following table:
		Market Condition			Market Condition
		Options Granted			Options Granted
		February 18, 2014			June 2, 2014
	Expected life (years) – officers		6			6
	Risk-free interest rate		1.9	%		2.1	%
	Volatility		70	%		65	%
	Dividends		None			None
	Number of options granted		640,000			400,000
	Fair value per share	$	1.2		$	0.34

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Summary of Changes in Accumulated Other Comprehensive Income (Loss)	'
	The following table summarizes the changes in accumulated other comprehensive income (loss) as of June 30, 2014:
		Unrealized Losses on
		Securities  Available-for-Sale
	Balance, as of December 31, 2013	$	(6,984	)
	Other comprehensive gain before reclassifications		14,385
	Amounts reclassified from accumulated other comprehensive income (loss)		—
	Net current period other comprehensive loss		14,385
	Balance, as of June 30, 2014	$	7,401

Loss_Per_Common_Share_Tables

Loss Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Antidilutive Securities Consist of Stock Options and Warrants	'
	Antidilutive securities consist of stock options and warrants outstanding as of the respective reporting period as follows:
		For the Three and Six Months Ended		For the Three and Six Months Ended
		June 30,		June 30,
		2014		2013
	Stock options outstanding		11,389,869		10,663,319
	Warrants outstanding		1,373,517		1,373,517
	Total antidilutive securities		12,763,386		12,036,836

Nature_of_Business_Additional_

Nature of Business - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014
	Segment
Nature Of Business [Abstract]	'
Reportable segments	1

Collaboration_Agreements_Addit

Collaboration Agreements - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jan. 31, 2013

Nov. 30, 2011

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

31-May-13

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jul. 31, 2014

Jun. 30, 2014

Nov. 30, 2011

Jun. 30, 2014

Leukemia and Lymphoma Society [Member]

Leukemia and Lymphoma Society [Member]

Leukemia and Lymphoma Society [Member]

Leukemia and Lymphoma Society [Member]

Leukemia and Lymphoma Society [Member]

Leukemia and Lymphoma Society [Member]

Genentech Inc [Member]

Genentech Inc [Member]

Genentech Inc [Member]

Genentech Inc [Member]

Genentech Inc [Member]

Genentech Inc [Member]

Genentech Inc [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Licensors

Subsequent Event [Member]

Leukemia and Lymphoma Society [Member]

Leukemia and Lymphoma Society [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Eligibility to receive contingent cash milestone payments under the collaboration

'

'

'

'

'

'

'

'

'

'

'

$115,000,000

'

$115,000,000

'

$115,000,000

'

'

'

'

'

Earned milestone payment

'

'

'

'

'

'

'

'

'

'

'

3,000,000

4,000,000

'

'

'

'

'

'

'

'

Amount earned for specified clinical development and regulatory objectives

'

'

'

'

'

'

'

'

'

'

'

59,000,000

'

59,000,000

'

59,000,000

'

'

'

'

'

License fees

3,000,000

4,000,000

3,000,000

4,000,000

'

'

'

'

'

'

'

'

'

3,000,000

4,000,000

3,000,000

4,000,000

3,000,000

'

'

'

Milestone amounts included accounts receivable

4,843,412

'

4,843,412

'

1,477,188

'

'

'

'

'

'

3,000,000

'

3,000,000

'

3,000,000

'

'

'

'

'

Number of university licensors in connection with the FDA-approval of Erivedge

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

Research and development expenses

3,328,976

3,166,639

6,474,906

5,795,096

'

'

'

'

'

'

'

'

'

150,000

200,000

150,000

200,000

'

'

'

'

Percentage of royalty on net sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

Recognized royalty revenues

1,823,935

805,312

3,112,183

1,469,712

'

'

'

'

'

'

'

'

'

1,823,935

805,312

3,112,183

1,469,712

'

'

'

'

Costs of royalty revenues recorded

91,837

40,265

156,985

73,485

'

'

'

'

'

'

'

'

'

91,837

40,265

156,985

73,485

'

'

'

'

Percentage of royalties earned

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

5.00%

5.00%

5.00%

'

'

'

'

Research and development revenue

-22,650

599,065

-26,265

806,100

'

'

'

'

'

'

'

'

'

31,376

46,653

71,237

93,994

'

'

'

'

Contra-revenues

'

'

'

'

'

'

'

'

'

'

'

'

'

54,153

'

139,583

'

'

'

'

'

Contribution of fund from LLS amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

Earned milestone payment

'

'

'

'

'

'

1,650,000

'

550,000

'

650,000

'

'

'

'

'

'

'

'

'

'

Revenue recognized, milestone achieved upon treatment of first patient of phase one trial

'

'

'

'

'

100,000

'

0

550,000

0

650,000

'

'

'

'

'

'

'

'

'

'

Royalty obligation on successful progressing of CUDC - 907 through clinical trials

'

'

'

'

'

'

'

'

'

$4,125,000

'

'

'

'

'

'

'

'

'

'

$10,000,000

Multiplier applied to milestone payments received to determine royalty obligation

'

'

'

'

'

'

'

'

'

2.5

'

'

'

'

'

'

'

'

'

'

'

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'	'
Assets measured at fair value on a nonrecurring basis	$0	$0
Liabilities measured at fair value on a nonrecurring basis	0	0
Certificate of deposit held by company	$1,002,861	$1,001,802

Fair_Value_Measurements_Financ

Fair Value Measurements - Financial Assets or Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Warrant liability	$67,910	$716,786	$853,778	$1,488,179
Fair Value Measurements Recurring [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Total assets at fair value	57,275,191	66,708,717	'	'
Warrant liability	67,910	716,786	'	'
Total liabilities at fair value	67,910	716,786	'	'
Fair Value Measurements Recurring [Member] | Cash Equivalents [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Money market funds	6,761,408	5,535,716	'	'
Corporate commercial paper, stock, bonds and notes	1,544,985	1,749,983	'	'
Municipal bonds	1,100,000	1,110,000	'	'
Fair Value Measurements Recurring [Member] | Short-and Long-term Investments [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
US government obligations	'	1,151,932	'	'
Corporate commercial paper, stock, bonds and notes	47,868,798	57,161,086	'	'
Fair Value Measurements Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Total assets at fair value	27,078,046	25,711,870	'	'
Warrant liability	'	'	'	'
Total liabilities at fair value	'	'	'	'
Fair Value Measurements Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Cash Equivalents [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Money market funds	6,761,408	5,535,716	'	'
Corporate commercial paper, stock, bonds and notes	'	'	'	'
Municipal bonds	'	'	'	'
Fair Value Measurements Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Short-and Long-term Investments [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
US government obligations	'	'	'	'
Corporate commercial paper, stock, bonds and notes	20,316,638	20,176,154	'	'
Fair Value Measurements Recurring [Member] | Other Observable Inputs (Level 2) [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Total assets at fair value	30,197,145	40,996,847	'	'
Warrant liability	'	'	'	'
Total liabilities at fair value	'	'	'	'
Fair Value Measurements Recurring [Member] | Other Observable Inputs (Level 2) [Member] | Cash Equivalents [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Money market funds	'	'	'	'
Corporate commercial paper, stock, bonds and notes	1,544,985	1,749,983	'	'
Municipal bonds	1,100,000	1,110,000	'	'
Fair Value Measurements Recurring [Member] | Other Observable Inputs (Level 2) [Member] | Short-and Long-term Investments [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
US government obligations	'	1,151,932	'	'
Corporate commercial paper, stock, bonds and notes	27,552,160	36,984,932	'	'
Fair Value Measurements Recurring [Member] | Unobservable Inputs (Level 3) [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Total assets at fair value	'	'	'	'
Warrant liability	67,910	716,786	'	'
Total liabilities at fair value	67,910	716,786	'	'
Fair Value Measurements Recurring [Member] | Unobservable Inputs (Level 3) [Member] | Cash Equivalents [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Money market funds	'	'	'	'
Corporate commercial paper, stock, bonds and notes	'	'	'	'
Municipal bonds	'	'	'	'
Fair Value Measurements Recurring [Member] | Unobservable Inputs (Level 3) [Member] | Short-and Long-term Investments [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
US government obligations	'	'	'	'
Corporate commercial paper, stock, bonds and notes	'	'	'	'

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value of Warrant Liability (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Fair Value Disclosures [Abstract]	'	'
Balance Beginning	$716,786	$1,488,179
Change in fair value of warrant liability	-648,876	-634,401
Balance Ending	$67,910	$853,778

Investments_Additional_Informa

Investments - Additional Information (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]	'	'
Available for sale securities weighted average maturity	'6 months	'4 months 21 days
Long-term investments	$3,257,209	$10,726,685
Amortized Cost	44,604,196	47,592,763
Corporate and Government-Secured Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available for sale securities weighted average maturity	'14 months 18 days	'14 months 9 days
Amortized Cost	3,257,489	10,727,958
Investment maturity period range start	'2015-07	'2015-01
Investment maturity period range end	'2015-11	'2015-05
Unrealized net losses	280	1,273
Certificates of Deposit [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Certificate of deposit	$1,002,861	$1,001,802
Minimum [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available for sale securities maturity period range	'1 month	'1 month
Maximum [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available for sale securities maturity period range	'12 months	'12 months

Investments_Summary_of_Amortiz

Investments - Summary of Amortized Cost, Unrealized Gains and Fair Value of Short-term Investments (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$44,604,196	$47,592,763
Unrealized Gain	14,547	9,046
Unrealized Loss	-7,153	-15,476
Fair Value	44,611,590	47,586,333
Corporate Bonds and Notes [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	44,604,196	47,091,593
Unrealized Gain	14,547	9,036
Unrealized Loss	-7,153	-15,476
Fair Value	44,611,590	47,085,153
US Government and Municipal Obligations [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	'	501,170
Unrealized Gain	'	10
Unrealized Loss	'	'
Fair Value	'	$501,180

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Other Current Assets [Member]

Other Current Assets [Member]

Other Assets [Member]

Other Assets [Member]

BioPharma-II [Member]

BioPharma-II [Member]

BioPharma-II [Member]

BioPharma-II [Member]

Curis Royalty [Member]

Curis Royalty [Member]

Curis Royalty [Member]

Curis Royalty [Member]

Curis Royalty [Member]

BioPharma-II [Member]

BioPharma-II [Member]

BioPharma-II [Member]

Debt [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal loan amount to Curis Royalty given by BioPharma under credit agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$30,000,000

Interest rate on loan to Curis Royalty given by BioPharma under credit agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.25%

Allocation of royalty payments received towards principal and interest subject to cap, cap amount for 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

Allocation of royalty payments received towards principal and interest subject to cap, cap amount for 2015

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

Percentage of loan that may be prepaid after January 01, 2017

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

105.00%

'

'

Accrued interest on loan amount to Curis Royalty given by BioPharma under credit agreement

'

'

1,835,064

'

'

'

'

'

'

'

'

'

'

'

'

312,150

298,935

'

Debt, current portion net of issuance costs

5,498,670

'

5,498,670

'

2,610,174

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt

24,372,065

'

24,372,065

'

27,945,186

'

'

'

'

'

'

'

'

24,372,065

27,945,186

'

'

'

Debt issue costs, current

'

'

'

'

'

53,529

53,503

'

'

'

'

'

'

'

'

'

'

'

Debt issue costs, long-term

'

'

'

'

'

'

'

78,351

105,105

'

'

'

'

'

'

'

'

'

Capitalized interest repaid

'

'

711,353

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment towards debt obligations

'

'

2,546,417

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated fair value of principal portion of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

30,490,000

'

'

'

'

Debt issuance costs gross

'

'

421,715

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt issuance cost

'

'

'

'

'

'

'

'

'

'

'

215,000

'

206,715

'

'

'

'

Interest expense recognized related to loan

$949,730

$957,742

$1,900,706

$1,905,544

'

'

'

'

'

$949,730

$957,742

$1,900,706

$1,905,544

'

'

'

'

'

Debt_Schedule_of_Debt_Issuance

Debt - Schedule of Debt Issuance Costs (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Debt [Line Items]	'	'
Total debt issuance costs	$126,797	$152,496
Debt, current	5,552,199	2,663,677
Debt, current portion net of issuance costs	5,498,670	2,610,174
Debt, long-term	24,450,416	28,050,291
Debt, net of current portion and issuance costs	24,372,065	27,945,186
Other Current Assets [Member]	'	'
Debt [Line Items]	'	'
Total debt issuance costs	51,466	51,441
Debt issue costs, current	-53,529	-53,503
Other Assets [Member]	'	'
Debt [Line Items]	'	'
Total debt issuance costs	75,331	101,055
Debt issue costs, long-term	($78,351)	($105,105)

Common_Stock_and_Warrant_Liabi2

Common Stock and Warrant Liability - Additional Information (Detail) (USD $)

0 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jan. 27, 2010

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jan. 27, 2010

2000 Stock Incentive Plan [Member]

2000 Stock Incentive Plan [Member]

2000 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

Other Income [Member]

Other Income [Member]

Other Income [Member]

Other Income [Member]

Warrants outstanding [Member]

Common Stock And Warrant Liability [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of registered direct offering, units

6,449,288

'

'

'

'

'

'

'

'

'

'

'

'

'

Registered direct offering, number of common stock per units

1

'

'

'

'

'

'

'

'

'

'

'

'

'

Registered direct offering, number of warrants per units

1

'

'

'

'

'

'

'

'

'

'

'

'

'

Direct offering purchase price per unit

2.52

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of warrant in terms of percentage of stock

'

'

'

'

'

'

'

'

'

'

'

'

'

0.25

Proceeds from registered direct offering of units, net of issuance costs

$14,942,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate number of shares of stock available to purchase using warrants

1,612,322

1,373,517

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised

'

238,805

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

3.55

'

'

'

'

'

'

'

'

'

'

'

'

Expiration of warrants

'

'2015-01

'

'

'

'

'

'

'

'

'

'

'

'

Change in fair value of warrant liability

'

648,876

634,401

'

'

'

'

'

'

557,253

333,141

648,876

634,401

'

Common stock surrendered to pay the exercise price

'

'

'

'

0

175,139

0

'

'

'

'

'

'

'

Option cost

'

$1,524,029

'

$1,524,029

'

'

'

$0

$632,755

'

'

'

'

'

Common_Stock_and_Warrant_Liabi3

Common Stock and Warrant Liability - Estimated Fair Value of Warrants (Detail) (Warrants outstanding [Member], USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Warrants outstanding [Member]	'	'
Common Stock And Warrant Liability [Line Items]	'	'
Fair value of the warrants	$67,910	$853,778
Expected term	'7 months 6 days	'1 year 7 months 6 days
Risk-free interest rate	0.06%	0.25%
Volatility	63.00%	47.20%
Dividends	'	'

Accrued_Liabilities_Accrued_Li

Accrued Liabilities - Accrued Liabilities (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]	'	'
Accrued compensation	$811,916	$1,267,954
Professional fees	219,450	166,200
Accrued interest on debt	312,150	298,935
Other	166,116	178,390
Total	$1,509,632	$1,911,479

Accounting_for_StockBased_Comp2

Accounting for Stock-Based Compensation - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 02, 2014	Feb. 18, 2014	Feb. 28, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
						Plans
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'	'	'	'
Share-based compensation, number of plans	'	'	'	'	'	2	'
Share based compensation arrangement vesting period	'	'	'	'	'	'60 days	'
Options issued	'	'	'	'	'	1,040,000	'
Aggregate intrinsic value of employee options outstanding	'	'	'	$1,906,000	'	$1,906,000	'
Intrinsic value of exercisable options	'	'	'	1,837,000	'	1,837,000	'
Weighted average grant-date fair values of stock options	$0.34	$1.20	'	'	'	$1.82	$2.14
Unrecognized compensation cost, net of estimated forfeitures	'	'	'	6,192,000	'	6,192,000	'
Intrinsic values of employee stock options exercised	'	'	'	'	'	105,000	1,598,000
Fair values of vested stock options	'	'	'	'	'	1,376,000	1,808,000
Stock options granted	400,000	640,000	640,000	'	'	400,000	'
Stock option granted, per share	'	'	$3.09	'	'	$1.75	'
Compensation expense related to employee and director stock option grants	'	'	'	108,366	'	156,377	'
Non-employee compensation expense	'	'	'	110,434	164,269	54,762	180,510
Stock options outstanding [Member]	'	'	'	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'	'	'	'
Compensation expense related to employee and director stock option grants	'	'	'	794,255	751,702	1,482,027	1,396,027
Tranche [Member]	'	'	'	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'	'	'	'
Aggregate expense	'	'	'	'	'	$905,000	'
2010 Plan [Member]	'	'	'	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'	'	'	'
Options granted	'	'	'	'	'	1,987,500	'
Share based compensation arrangement vesting period	'	'	'	'	'	'4 years	'
Options granted with four year vesting period	'	'	'	'	'	947,500	'
2010 Plan [Member] | Non-Employee Directors [Member]	'	'	'	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'	'	'	'
Options granted to employee directors with one year vesting period	'	'	'	'	'	235,000	'
Share based compensation, vesting period of options	'	'	'	'	'	'1 year	'
Unrecognized compensation cost, weighted average period for recognition, years	'	'	'	'	'	'2 years 9 months 18 days	'

Accounting_for_StockBased_Comp3

Accounting for Stock-Based Compensation - Valuation Assumptions Used to Calculate Fair Value of Employee Options Awarded (Detail) (USD $)	0 Months Ended		1 Months Ended	6 Months Ended
	Jun. 02, 2014	Feb. 18, 2014	Feb. 28, 2014	Jun. 30, 2014	Jun. 30, 2013
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'	'
Expected life (years)	'6 years	'6 years	'	'	'
Risk-free interest rate	2.10%	1.90%	'	'	'
Volatility	65.00%	70.00%	'	'	'
Dividends	'	'	'	'	'
Number of options granted	400,000	640,000	640,000	400,000	'
Fair value per share	$0.34	$1.20	'	$1.82	$2.14
Minimum [Member]	'	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'	'
Risk-free interest rate	'	'	'	1.85%	1.00%
Volatility	'	'	'	70.00%	70.00%
Maximum [Member]	'	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'	'
Risk-free interest rate	'	'	'	2.20%	1.60%
Volatility	'	'	'	71.00%	72.00%
Employees [Member]	'	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'	'
Expected life (years)	'	'	'	'6 years	'6 years
Officers and Directors [Member]	'	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'	'
Expected life (years)	'	'	'	'7 years	'7 years

Accounting_for_StockBased_Comp4

Accounting for Stock-Based Compensation - Employee and Non-Employee Share Based Compensation Expense Allocation (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'
Total stock-based compensation expense	$683,821	$915,971	$1,427,265	$1,576,537
Research and Development Expenses [Member]	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'
Total stock-based compensation expense	108,803	289,640	300,748	496,519
General and Administrative Expenses [Member]	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'
Total stock-based compensation expense	$575,018	$626,331	$1,126,517	$1,080,018

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014
			Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Accumulated other comprehensive income (loss), net of tax, Beginning balance	$7,401	($6,984)	($6,984)
Other comprehensive gain before reclassifications	'	'	14,385
Amounts reclassified from accumulated other comprehensive income (loss)	'	'	'
Net current period other comprehensive loss	'	'	14,385
Accumulated other comprehensive income (loss), net of tax, Ending balance	$7,401	($6,984)	$7,401

Loss_Per_Common_Share_Antidilu

Loss Per Common Share - Antidilutive Securities Consist of Stock Options and Warrants (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Total antidilutive securities	12,763,386	12,036,836	12,763,386	12,036,836
Stock options outstanding [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Total antidilutive securities	11,389,869	10,663,319	11,389,869	10,663,319
Warrants outstanding [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Total antidilutive securities	1,373,517	1,373,517	1,373,517	1,373,517

Related_Party_Transaction_Addi

Related Party Transaction - Additional Information (Detail) (Mr. Passeri [Member], USD $)	0 Months Ended	3 Months Ended	6 Months Ended
	Jun. 02, 2014	Jun. 30, 2014	Jun. 30, 2014
Related Party Transaction [Line Items]	'	'	'
Compensation received for participation, per year	$100,000	'	'
Consulting agreement date	'	'	2-Jun-14
Consulting agreement term	'	'	'1 year
Consulting service hours per month	'	'	'120 hours
Consulting fees per month	'	'	32,500
Consulting agreement end date	'	'	1-Jun-15
Consulting agreement, recognized expenses	'	30,333	30,333
After June 1, 2015 [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Consulting fees per month	'	'	$30,000
Consulting agreement termination notice period	'	'	'30 days